Issue Date: January 14, 2013
Heptares, Cubist Join On GPCR Research
Heptares Therapeutics and Cubist Pharmaceuticals will collaborate on the discovery of new therapies targeting G protein-coupled receptors (GPCRs) using Heptares’ drug discovery platform. Under the agreement, Cubist will hold exclusive worldwide rights to develop and commercialize drug candidates identified by the partners. Cubist will pay Heptares $5.5 million up front and up to $4 million in research funding, plus milestones and royalties, for the first drug target. GPCRs are membrane proteins involved in a broad range of biological processes and diseases.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society